Xenon Pharmaceuticals Inc.
XENE
$42.88
-$0.63-1.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 35.25% | 50.87% | 38.31% | 44.79% | 32.86% |
| Gross Profit | -35.25% | -50.87% | -21.36% | -44.79% | -32.86% |
| SG&A Expenses | 15.42% | -0.81% | 28.71% | 42.68% | 30.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.76% | 36.36% | 35.90% | 44.29% | 32.31% |
| Operating Income | -30.76% | -36.36% | -23.20% | -44.29% | -32.31% |
| Income Before Tax | -42.96% | -46.48% | -35.99% | -54.70% | -29.81% |
| Income Tax Expenses | 311.56% | -87.99% | 3.64% | -1,777.07% | -103.82% |
| Earnings from Continuing Operations | -44.76% | -46.24% | -35.71% | -46.81% | -29.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.76% | -46.24% | -35.71% | -46.81% | -29.57% |
| EBIT | -30.76% | -36.36% | -23.20% | -44.29% | -32.31% |
| EBITDA | -31.07% | -36.71% | -23.31% | -45.42% | -35.33% |
| EPS Basic | -42.34% | -43.86% | -33.82% | -31.04% | -9.75% |
| Normalized Basic EPS | -40.56% | -44.09% | -34.09% | -37.64% | -8.86% |
| EPS Diluted | -42.34% | -43.86% | -33.82% | -31.04% | -9.75% |
| Normalized Diluted EPS | -40.56% | -44.09% | -34.09% | -37.64% | -8.86% |
| Average Basic Shares Outstanding | 1.70% | 1.65% | 1.41% | 12.03% | 18.07% |
| Average Diluted Shares Outstanding | 1.70% | 1.65% | 1.41% | 12.03% | 18.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |